The historical rank and industry rank for Arctic Bioscience AS's Net Margin % or its related term are showing as below:
OSL:ABS'
s Net Margin % Range Over the Past 10 Years
Min: -197.91 Med: -106.27 Max: -6.88
Current: -102.32
OSL:ABS's Net Margin % is ranked worse than 51.86% of 939
companies
in the Biotechnology industry
Industry Median: -88.29
vs OSL:ABS: -102.32
Arctic Bioscience AS (OSL:ABS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Arctic Bioscience AS Net Margin % Related Terms
Arctic Bioscience AS Net Margin % Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ABS vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Arctic Bioscience AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a Net Margin % of -96.57% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Arctic Bioscience AS and its competitors. According to the industry distribution chart, Arctic Bioscience AS ranks #487 out of 939 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Arctic Bioscience AS's Net Margin % too high?
Arctic Bioscience AS's current Net Margin % is -96.57%. Based on the distribution chart, Arctic Bioscience AS ranks #487 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arctic Bioscience AS has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #487 out of 939 companies for Net Margin %. This places Arctic Bioscience AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Arctic Bioscience AS and its competitors. Arctic Bioscience AS's current Net Margin % is -96.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.61, compared to a current price of kr3.19 — trading 69.9% below its estimated fair value. The current Net Margin % is -96.57%. Arctic Bioscience AS's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Net Margin % is -96.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.19 is trading 69.9% below its estimated GF Value™ of kr10.61.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
Net Margin %: -96.57%
GF Value™: kr10.61 vs. price of kr3.19 (69.9% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
55GF Score
Get the complete analysis for OSL:ABS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
